Contributions of the international plant science community to the fight against infectious diseases in humans—part 2: Affordable drugs in edible plants for endemic and re‐emerging diseases
Authors:
Open Access
- 28 June 2021
- journal article
- review article
- Published by Wiley in Plant Biotechnology Journal
- Vol. 19 (10) , 1921-1936
Abstract
Summary: The fight against infectious diseases often focuses on epidemics and pandemics, which demand urgent resources and command attention from the health authorities and media. However, the vast majority of deaths caused by infectious diseases occur in endemic zones, particularly in developing countries, placing a disproportionate burden on underfunded health systems and often requiring international interventions. The provision of vaccines and other biologics is hampered not only by the high cost and limited scalability of traditional manufacturing platforms based on microbial and animal cells, but also by challenges caused by distribution and storage, particularly in regions without a complete cold chain. In this review article, we consider the potential of molecular farming to address the challenges of endemic and re‐emerging diseases, focusing on edible plants for the development of oral drugs. Key recent developments in this field include successful clinical trials based on orally delivered dried leaves of Artemisia annua against malarial parasite strains resistant to artemisinin combination therapy, the ability to produce clinical‐grade protein drugs in leaves to treat infectious diseases and the long‐term storage of protein drugs in dried leaves at ambient temperatures. Recent FDA approval of the first orally delivered protein drug encapsulated in plant cells to treat peanut allergy has opened the door for the development of affordable oral drugs that can be manufactured and distributed in remote areas without cold storage infrastructure and that eliminate the need for expensive purification steps and sterile delivery by injection.Keywords
Funding Information
- Bayer
- Fundação para a Ciência e a Tecnologia (UIDB/04551/2020 (GREEN‐IT ‐ Bioresources for Susta)
- Ministerio de Ciencia e Innovación (AGL2017‐85377‐R, PGC2018‐097655‐B‐I00, RTI2018‐097613‐B‐I00)
- Biotechnology and Biological Sciences Research Council (BBS/E/J/000PR9794, Grant BB/L020955/1)
- Generalitat de Catalunya (Grups Consolidats2017‐SGR828)
- Empresa Brasileira de Pesquisa Agropecuária
- Novo Nordisk
This publication has 206 references indexed in Scilit:
- Robust production of virus‐like particles and monoclonal antibodies with geminiviral replicon vectors in lettucePlant Biotechnology Journal, 2011
- A Plant-Produced Pfs230 Vaccine Candidate Blocks Transmission of Plasmodium falciparumClinical and Vaccine Immunology, 2011
- Expression of dengue-3 premembrane and envelope polyprotein in lettuce chloroplastsPlant Molecular Biology, 2011
- Low‐cost production of proinsulin in tobacco and lettuce chloroplasts for injectable or oral delivery of functional insulin and C‐peptidePlant Biotechnology Journal, 2010
- Expression and characterization of antimicrobial peptides Retrocyclin‐101 and Protegrin‐1 in chloroplasts to control viral and bacterial infectionsPlant Biotechnology Journal, 2010
- Monoclonal antibody produced in plants efficiently treats West Nile virus infection in miceProceedings of the National Academy of Sciences, 2010
- The Role of Heterologous Chloroplast Sequence Elements in Transgene Integration and ExpressionPlant Physiology, 2010
- Chloroplast‐derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable deliveryPlant Biotechnology Journal, 2010
- Plastid production of protein antibiotics against pneumonia via a new strategy for high-level expression of antimicrobial proteinsProceedings of the National Academy of Sciences, 2009
- The pathogenic basis of malariaNature, 2002